The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Three days of CIV rh-Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic, non-squamous non–small cell lung cancer (NSCLC): A open label, multicenter, phase II and cohort study (ENPOWER).
 
Dong Wang
No Relationships to Disclose
 
Yan Feng
No Relationships to Disclose
 
Yuju Bai
No Relationships to Disclose
 
Hu Ma
No Relationships to Disclose
 
Li Huang
No Relationships to Disclose
 
Tienian Zhu
No Relationships to Disclose
 
Haihong Qian
No Relationships to Disclose
 
Yanping Li
No Relationships to Disclose
 
Xinjian Fang
No Relationships to Disclose
 
Biyong Ren
No Relationships to Disclose